Cabaletta Bio, Inc. (CABA)Healthcare | Biotechnology | Philadelphia, United States | NasdaqGS
2.77 USD
-0.21
(-7.059%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 2.76 -0.01 (-0.005%) ⇩ (July 13, 2026, 7:56 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:27 a.m. EDT
Cabaletta Bio presents a stark dichotomy between its precarious financial reality and its high-risk, high-reward biotech narrative. Fundamentally, the company is in distress: it is burning massive cash, reporting negative free cash flow of nearly $91 million, and carrying a debt-to-equity ratio that suggests a fragile balance sheet. The stock has suffered a catastrophic multi-year decline, dropping roughly 85% over the last five years, with the most recent annual performance showing another steep drop of nearly 79%. While the recent news of a $150M equity raise and positive early trial data offers a glimmer of hope for survival and potential future growth, the current fundamentals do not support a 'buy' thesis. The market has clearly priced in significant deterioration, leaving the stock trading at a fraction of its historical value. For investors, this is a speculative gamble on a clinical trial success story rather than a sound investment based on current earnings or stability. The lack of any dividend yield further underscores the company's focus on capital preservation through financing rounds rather than shareholder returns. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.086903 |
| AutoARIMA | 0.089749 |
| AutoETS | 0.089907 |
| MSTL | 0.091940 |
| MSTL_126 | 0.129594 |
| MSTL_90 | 0.136767 |
| MSTL_90_126 | 0.148145 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 0.33 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.141 |
| Excess Kurtosis | -1.03 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 25.604 |
| Market Cap | 450,846,528 |
| Forward P/E | -1.95 |
| Beta | 3.26 |
| Website | https://www.cabalettabio.com |
As of July 11, 2026, 3:27 a.m. EDT: Speculators are positioning defensively with heavy put volume and open interest at strikes below the current price ($2.50 and $2.00), while call activity remains sparse and concentrated near-the-money. Implied volatility is elevated for longer-dated contracts, suggesting a fear of significant downside or binary event risk rather than a bullish catalyst. The lack of significant out-of-the-money call positioning indicates limited speculative upside conviction in the near term.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.760355 |
| Address1 | 2,929 Arch Street |
| Address2 | Suite 600 |
| All Time High | 26.35 |
| All Time Low | 0.59 |
| Ask | 3.54 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 8,467,580 |
| Average Daily Volume3 Month | 4,935,600 |
| Average Volume | 4,935,600 |
| Average Volume10Days | 8,467,580 |
| Beta | 3.257 |
| Bid | 2.11 |
| Bid Size | 2 |
| Book Value | 0.928 |
| City | Philadelphia |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.765 |
| Current Ratio | 2.947 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 2.96 |
| Day Low | 2.735 |
| Debt To Equity | 25.604 |
| Display Name | Cabaletta Bio |
| Earnings Timestamp | 1,778,761,800 |
| Earnings Timestamp End | 1,786,019,400 |
| Earnings Timestamp Start | 1,786,019,400 |
| Ebitda | -177,903,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.027 |
| Enterprise Value | 360,661,504 |
| Eps Current Year | -1.33795 |
| Eps Forward | -1.42001 |
| Eps Trailing Twelve Months | -1.65 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.3222 |
| Fifty Day Average Change | -0.55719995 |
| Fifty Day Average Change Percent | -0.16772017 |
| Fifty Two Week Change Percent | 76.0355 |
| Fifty Two Week High | 4.23 |
| Fifty Two Week High Change | -1.4649999 |
| Fifty Two Week High Change Percent | -0.34633568 |
| Fifty Two Week Low | 1.26 |
| Fifty Two Week Low Change | 1.5050001 |
| Fifty Two Week Low Change Percent | 1.1944445 |
| Fifty Two Week Range | 1.26 - 4.23 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,572,010,200,000 |
| Float Shares | 142,902,854 |
| Forward Eps | -1.42001 |
| Forward P E | -1.9471695 |
| Free Cashflow | -90,822,872 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 156 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01005 |
| Held Percent Institutions | 0.64319 |
| Implied Shares Outstanding | 163,054,796 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. |
| Long Name | Cabaletta Bio, Inc. |
| Market | us_market |
| Market Cap | 450,846,528 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_590735322 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -175,428,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 485,088,018 |
| Number Of Analyst Opinions | 8 |
| Open | 2.92 |
| Operating Cashflow | -142,839,008 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 267 759 3100 |
| Post Market Change | -0.0050001144 |
| Post Market Change Percent | -0.18083596 |
| Post Market Price | 2.76 |
| Post Market Time | 1,783,986,991 |
| Previous Close | 2.975 |
| Price Eps Current Year | -2.0665946 |
| Price Hint | 4 |
| Price To Book | 2.979526 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.81 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.21 |
| Regular Market Change Percent | -7.05882 |
| Regular Market Day High | 2.96 |
| Regular Market Day Low | 2.735 |
| Regular Market Day Range | 2.735 - 2.96 |
| Regular Market Open | 2.92 |
| Regular Market Previous Close | 2.975 |
| Regular Market Price | 2.765 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 4,310,122 |
| Return On Assets | -0.71580005 |
| Return On Equity | -1.5603399 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 163,054,796 |
| Shares Percent Shares Out | 0.20889999 |
| Shares Short | 34,060,216 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 22,943,123 |
| Short Name | Cabaletta Bio, Inc. |
| Short Percent Of Float | 0.23120001 |
| Short Ratio | 6.07 |
| Source Interval | 15 |
| State | PA |
| Symbol | CABA |
| Target High Price | 30.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 13.375 |
| Target Median Price | 13.5 |
| Total Cash | 116,635,000 |
| Total Cash Per Share | 0.715 |
| Total Debt | 26,450,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.65 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.838375 |
| Two Hundred Day Average Change | -0.07337499 |
| Two Hundred Day Average Change Percent | -0.025851054 |
| Type Disp | Equity |
| Volume | 4,310,122 |
| Website | https://www.cabalettabio.com |
| Zip | 19,104 |